Vuilleumier N - Search Results

1

High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases.

Hafiane A, Favari E, Daskalopoulou SS, Vuilleumier N, Frias MA. Hafiane A, et al. Among authors: vuilleumier n. Metabolism. 2020 Mar;104:154141. doi: 10.1016/j.metabol.2020.154141. Epub 2020 Jan 8. Metabolism. 2020. PMID: 31923386 Review.

2

Pro- or anti-inflammatory role of apolipoprotein A-1 in high-density lipoproteins?

Vuilleumier N, Dayer JM, von Eckardstein A, Roux-Lombard P. Vuilleumier N, et al. Swiss Med Wkly. 2013 May 25;143:w13781. doi: 10.4414/smw.2013.13781. eCollection 2013. Swiss Med Wkly. 2013. PMID: 23740387 Free article. Review.

3

Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions.

Montecucco F, Favari E, Norata GD, Ronda N, Nofer JR, Vuilleumier N. Montecucco F, et al. Among authors: vuilleumier n. Handb Exp Pharmacol. 2015;224:455-82. doi: 10.1007/978-3-319-09665-0_14. Handb Exp Pharmacol. 2015. PMID: 25522998 Review.

4

Biomarkers for cardiovascular risk assessment in autoimmune diseases.

Teixeira PC, Ferber P, Vuilleumier N, Cutler P. Teixeira PC, et al. Among authors: vuilleumier n. Proteomics Clin Appl. 2015 Feb;9(1-2):48-57. doi: 10.1002/prca.201400125. Proteomics Clin Appl. 2015. PMID: 25523513 Review.

5

Improving reconstituted HDL composition for efficient post-ischemic reduction of ischemia reperfusion injury.

Brulhart-Meynet MC, Braunersreuther V, Brinck J, Montecucco F, Prost JC, Thomas A, Galan K, Pelli G, Pedretti S, Vuilleumier N, Mach F, Lecour S, James RW, Frias MA. Brulhart-Meynet MC, et al. Among authors: vuilleumier n. PLoS One. 2015 Mar 17;10(3):e0119664. doi: 10.1371/journal.pone.0119664. eCollection 2015. PLoS One. 2015. PMID: 25781943 Free PMC article.

6

CD14 as a Mediator of the Mineralocorticoid Receptor-Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on Cardiomyocytes.

Mannic T, Satta N, Pagano S, Python M, Virzi J, Montecucco F, Frias MA, James RW, Maturana AD, Rossier MF, Vuilleumier N. Mannic T, et al. Among authors: vuilleumier n. Endocrinology. 2015 Dec;156(12):4707-19. doi: 10.1210/en.2015-1605. Epub 2015 Sep 22. Endocrinology. 2015. PMID: 26393305

7

Impact of long distance rowing on biological health: A pilot study.

Frias MA, Virzi J, Golaz O, Gencer B, Mach F, Vuilleumier N. Frias MA, et al. Among authors: vuilleumier n. Clin Biochem. 2018 Feb;52:142-147. doi: 10.1016/j.clinbiochem.2017.11.018. Epub 2017 Dec 2. Clin Biochem. 2018. PMID: 29198760

8

Pharmacological Intervention to Modulate HDL: What Do We Target?

Woudberg NJ, Pedretti S, Lecour S, Schulz R, Vuilleumier N, James RW, Frias MA. Woudberg NJ, et al. Among authors: vuilleumier n. Front Pharmacol. 2018 Jan 22;8:989. doi: 10.3389/fphar.2017.00989. eCollection 2017. Front Pharmacol. 2018. PMID: 29403378 Free PMC article. Review.

9

ELISA methods comparison for the detection of auto-antibodies against apolipoprotein A1.

Frias MA, Virzi J, Batuca J, Pagano S, Satta N, Delgado Alves J, Vuilleumier N. Frias MA, et al. Among authors: vuilleumier n. J Immunol Methods. 2019 Jun;469:33-41. doi: 10.1016/j.jim.2019.03.011. Epub 2019 Mar 27. J Immunol Methods. 2019. PMID: 30926534

10

Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects.

Vuilleumier N, Pagano S, Montecucco F, Quercioli A, Schindler TH, Mach F, Cipollari E, Ronda N, Favari E. Vuilleumier N, et al. J Clin Med. 2019 Aug 15;8(8):1225. doi: 10.3390/jcm8081225. J Clin Med. 2019. PMID: 31443207 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

184 results

Search Page